Researchers reported a strategy to reverse osimertinib resistance in non-small cell lung cancer by silencing NUP62. The approach targets resistance in patients whose tumors evolve beyond the efficacy of the third-generation EGFR TKI osimertinib, which remains a frontline therapy for EGFR-activating mutations. The report frames NUP62 as a lever in the resistance biology, proposing that inhibiting or silencing NUP62 can re-sensitize resistant tumors to EGFR TKI treatment. If borne out in further preclinical validation and translational work, it could inform next-step combination designs aimed at extending durability of response. For biotech pipelines, the headline is notable for offering a potential new resistance mechanism and a candidate target for future studies in EGFR-mutant disease.